Our program is internationally recognized for its efforts to enable patients with non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, and related disorders to have the best possible clinical outcome, including cure when possible. For many of these disorders, chemotherapy and radiation therapy have been the primary treatments, and can often be quite successful. Patients come to our center for evaluation and treatment from throughout the New York metro area, as well as other parts of the country and world.
At the NewYork-Presbyterian Hospital/Weill Cornell Center for Lymphoma and Myeloma, where I am Clinical Director, we have developed an outstanding team of physicians (including medical oncologists, radiation oncologists, pathologists, and others), nurses, and related health care personnel in order to optimally serve patients with these disorders. As we have a clinical focus in these areas, we are well versed in standard therapies, as well as their usual complications. Our experience with lymphoma and other treatment regimens is important to many patients undergoing therapy.
However, we are not satisfied with current outcomes for patients with lymphoma and myeloma as a group. We are working diligently to try to improve cure rates, as well as to improve remissions and extend life for other patients, while maintaining and improving its quality. Many of our patients are interested in clinical trials for their disorder, often in addition to "standard" therapies. Our focus has been primarily on "immunotherapies," which can work with the immune system to kill tumor cells. However, we collaborate with laboratory scientists at Weill Cornell, biotechnology and pharmaceutical companies, and other leading lymphoma research groups both nationally and internationally to bring the most promising developments to our patients.
Many of our clinical trials are offered in conjunction with the National Cancer Institute, and our research program is otherwise in part also supported by the National Institutes of Health. Some clinical trials can be administered in conjunction with community oncologists, in order to minimize inconvenience and travel for the patient. Additional details are located in the "Research Profile" section on this page of the website.
Lymphomas as a group are a complex set of disorders. While many patients are treated here as their primary oncologist, others come for a second opinion while having their primary oncologic care with a local physician, having us follow along as needed. Others are referred (or otherwise seek care) for access to novel agents as part of clinical trials. We are pleased to provide care in any fashion that would be of assistance to patients, in order to help them achieve the best possible therapeutic results. Patients or physicians with any questions about our lymphoma and myeloma care programs, clinical trials, or related issues should feel free to contact us for more information.
EDUCATION:
B.A. - Johns Hopkins University, 1986
M.D. - University of Virginia School of Medicine, 1990
PROFESSIONAL TRAINING:
Intern and Resident, Department of Medicine, New York Hospital - Cornell Medical Center, 1991-1993
Fellow, Division of Hematology and Oncology, Department of Medicine, New York Hospital - Cornell Medical Center, 1993 - 1996
POSITIONS HELD:
Chief Resident, Department of Medicine, New York Hospital - Cornell Medical Center, 1996 - 1997
Assistant Professor of Medicine, Weill Medical College of Cornell University, 1997 - 2004
Assistant Attending Physician, NewYork-Presbyterian Hospital, New York Weill Cornell Center, 1995 - 2004
Associate Professor of Medicine, Weill Medical College of Cornell University 2004 - 2007
Professor of Medicine, Weill Cornell Medical College 2007 - present
Associate Attending Physician, NewYork-Presbyterian Hospital/New York Weill Cornell Center 2004 - 2007
Attending Physician, NewYork-Presbyterian Hospital 2007 - present
Director, Inpatient Oncology Unit, NewYork-Presbyterian Hospital/New York Weill Cornell Center, 1997 - 2004
Clinical Director, NewYork-Presbyterian Hospital/Weill Cornell Center for Lymphoma and Myeloma, 1998 - present
Medical Director, Oncology Services, NewYork-Presbyterian Hospital/New York Weill Cornell Center, 1999 - 2004
Associate Director, Clinical Research Hematology and Medical Oncology 2004 - 2006
Director, Hematology/Oncology Clinical Research Program 2007 - present
Director, Hematology-Oncology Fellowship Training Program 2003 - 2005
Chief, Lymphoma/Myeloma Service, Division of Hematology and Oncology, Weill Medical College of Cornell University, NewYork-Presbyterian Hospital, New York Weill Cornell Center, 2001 - present
PROFESSIONAL MEMBERSHIPS:
Editorial Board, Blood
Editorial Board, Journal of Clinical Oncology
American College of Physicians
American Federation for Clinical Research
American Society of Hematology
American Society of Clinical Oncology
Cancer and Leukemia Group B (CALGB), National Cancer Institute, General Member and Non-Hodgkin's Lymphoma Working Group Leader, Lymphoma Core Committee, and Weill Cornell Principal Investigator, CALGB
New York Cancer Society
Scientific Advisory Board, Lymphoma Research Foundation
OTHER PROFESSIONAL RESPONSIBILITIES:
Radiation Safety Committee, NewYork-Presbyterian Hospital, New York Weill Cornell Center
Oncology Operations Council, NewYork-Presbyterian Hospital, New York Weill Cornell Center
Chair, Clinical Protocol Review Committee, Division of Hematology/Oncology, Weill Medical College of Cornell University
Intern Selection Committee, Department of Medicine, NewYork-Presbyterian Hospital, New York Weill Cornell Center
Ward teaching attending, Medical student laboratory session instructor, Hematology/Oncology student/housestaff lectures, Medical Housestaff Morning Report Attending, Lymphoma Clinic attending, Fellow research mentor, Department of Medicine, Weill Medical College of Cornell University, NewYork-Presbyterian Hospital, New York Cornell Center
HONORS AND AWARDS:
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Ellen Glesby Cohen Award, Lymphoma Research Foundation
National Institutes of Health K23 Award (Mentored Patient-Oriented Research Career Development Award) - "Novel Monoclonal Antibody Therapies for Lymphoma"
Non-Hodgkins Lymphoma Working Group Leader, Lymphoma Core Committee, Cancer and Leukemia Group B (CALGB), National Cancer Institute
"Top Doctors," New York Metro Area 2004, 2005, 2006, 2007 Castle Connolly Guide
INVITED LECTURES:
American Society of Hematology
American Society of Clinical Oncology
European Hematology Association
Japan Society of Hematology
Chemotherapy Foundation Symposium
Society for Biological Therapy
Invited lectures at numerous other national and international meetings/symposia
REVIEWER:
Editorial Board, Journal of Clinical Oncology
Editorial Board, Blood
Editorial Board, Clinical Lymphoma and Myeloma
Reviewer:
Annals of Internal Medicine
Blood
Cancer
Cancer Investigation
Leukemia and Lymphoma
Chief Medical Resident, New York Hospital - Cornell Medical Center
Medical Housestaff Program Director's Award, New York Hospital - Cornell Medical Center
Outstanding Medical Student Award, Medical Alumni Association, University of Virginia School of Medicine
Raven Society, University of Virginia
